199 related articles for article (PubMed ID: 20187106)
1. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.
Awad T; Thorlund K; Hauser G; Stimac D; Mabrouk M; Gluud C
Hepatology; 2010 Apr; 51(4):1176-84. PubMed ID: 20187106
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
Hauser G; Awad T; Thorlund K; Štimac D; Mabrouk M; Gluud C
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005642. PubMed ID: 24585451
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
4. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.
Hartwell D; Cooper K; Frampton GK; Baxter L; Loveman E
Health Technol Assess; 2014 Oct; 18(65):i-xxii, 1-202. PubMed ID: 25350588
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
[TBL] [Abstract][Full Text] [Related]
8. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
Witthoeft T; Hueppe D; John C; Goelz J; Heyne R; Moeller B; Teuber G; Wollschlaeger S; Baumgarten A; Simon KG; Moog G; Dikopoulos N; Mauss S
J Viral Hepat; 2010 Jul; 17(7):459-68. PubMed ID: 20158603
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
[TBL] [Abstract][Full Text] [Related]
12. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
13. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: pegylated interferon α-2a achieves higher early virological responses than α-2b in chronic hepatitis C.
Romero-Gómez M; Planas R; Ampuero J; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Turnes J
Aliment Pharmacol Ther; 2013 Jun; 37(11):1065-73. PubMed ID: 23581537
[TBL] [Abstract][Full Text] [Related]
15. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
Singal AK; Jampana SC; Anand BS
Dig Dis Sci; 2011 Aug; 56(8):2221-6. PubMed ID: 21643737
[TBL] [Abstract][Full Text] [Related]
17. Comparison of peginterferon and interferon in treating Chinese patients with chronic hepatitis C.
Zhao S; Liu E; Yu H; Yang H; Xun M; Xue X; Song J; Xu K; Chu Y
Hepatogastroenterology; 2008; 55(84):1047-54. PubMed ID: 18705326
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.
Perry CM; Jarvis B
BioDrugs; 2002; 16(3):213-7. PubMed ID: 12102649
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
